DETERMINANT led by ANTABIO

A French integrated solution to combat antimicrobial resistance in hospitals

What is at stake

Antimicrobial resistance is a major public health issue, responsible for 35,000 deaths per year in Europe. Multidrug-resistant hospital-acquired infections affect particularly vulnerable patients and undermine essential aspects of modern medicine, particularly in intensive care and critical care. In this context, developing more effective therapeutic and diagnostic solutions is a health priority. To address this challenge, Antabio, a French biopharmaceutical company specializing in the development of innovative treatments against multidrug-resistant bacterial infections, is coordinating the DETERMINANT project alongside Toulouse School of Economics.

The project

DETERMINANT (Diagnostics, Therapies, and Economic Incentives for Antimicrobial Resistance) is developing an integrated solution that combines a new antibiotic and a health economic approach designed to ensure market access and the sustainability of the model.

The consortium brings together tow complementary French partners: Antabio, the project leader and developer of MEM-PIL; and the Toulouse School of Economics, which is leading the economic modeling and valuation work. This complementarity allows the scientific, clinical, industrial, and economic dimensions of the project to be addressed collectively.

The ambition

The project is based on tow complementary components: the MEM-PIL product, a combination of a hospital-grade antibiotic, meropenem, and an innovative resistance inhibitor, pilabactam, for the treatment of severe nosocomial infections caused by multidrug-resistant Gram-negative bacilli; and an economic model designed to demonstrate the value of these two solutions and prepare the groundwork for their market entry.

Project Innovations

DETERMINANT offers a distinctive therapeutic innovation. MEM-PIL is designed to provide broad-spectrum coverage against several priority pathogens, including carbapenem-resistant Enterobacteriaceae, carbapenem-resistant Acinetobacter baumannii, and Pseudomonas aeruginosa, with a treatment approach tailored to either targeted or probabilistic therapy, depending on the clinical context.

DETERMINANT also incorporates a health economic innovation aimed at assessing the cost of inaction in the face of resistant nosocomial infections, analyzing mechanisms to support innovation, and proposing models that reconcile the appropriate use and economic viability of MEM-PIL.

A consortium dedicated to health sovereignty

By combining therapy and health economics, DETERMINANT helps strengthen France’s health and technological sovereignty in the field of antibiotic resistance and build an integrated response to a major public health challenge. IDCluster supports this initiative by acting as a project accelerator, helping to structure the project, mitigate risks, and facilitate its transition to industrial-scale production.